Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Better Bioprinting by Light-sheet Lithography

Descripción del proyecto

Un novedoso método de litografía descendente para la bioimpresión superará los desafíos actuales

La ingeniería de tejidos ha avanzado significativamente en los últimos decenios. Hoy en día, la bioimpresión es el método más prometedor para producir tejidos artificiales funcionales. La impresión capa por capa en orden ascendente convencional es la norma, pero todavía existen importantes desafíos, como la viabilidad y las limitaciones técnicas para la velocidad de impresión y la resolución espacial. El equipo del proyecto B-BRIGHTER, financiado con fondos europeos, está elaborando un método de litografía descendente que utiliza la iluminación digital de hojas de luz a velocidad ultraalta para la fotorreticulación selectiva de capas de hidrogeles cargados de células que imitan determinados tejidos. Este método creará rápidamente geometrías tridimensionales funcionales con una gran resolución espacial. El equipo formulará un caso de negocio validado para respaldar una vía de acceso al mercado.

Objetivo

Bioprinting is considered the most promising method to produce functional engineered tissues with physiological properties. Successful tissue engineering will open research avenues for drug testing and therapeutic and will therefore raise much interest not only in the academia, but also pharma and clinical sectors. Current bioprinting methods are limited by combinations of insufficient speed, spatial resolution and cell viability. Since these technologies often suffer from poor spatial resolution and inability to control biomechanical properties, they fail to mimic the heterogeneous nature of native tissues. B-BRIGHTER aims to develop a novel bioprinting technology able to produce engineered tissues with high spatial resolution at high printing speed using an original top-down lithography approach. In contrast with current bottom up, layer-by-layer bioprinting methods, B-BRIGHTER aims at ultra high-speed digital light-sheet illumination strategy to selectively photo-crosslink cell-laden hydrogels mimicking specific tissues, in confined voxels and produce three-dimensional complex geometries. Previous advances from the BRIGHTER project will be extended by building complex bioengineered skin, cornea and gut tissue models, all of which represent pioneering examples for bioengineering, and its application for cell therapy, drug discovery and toxicology. Together with the work on patterning technology, bioink and application, a basis will be established for formulating a valid business case for a bioprinting product. The work on exploitation activities will ultimately result in a go-no go decision for the industrialisation of a bioprinting product and a commercial path forward. Ultimately, the goal of the B-BRIGHTER project is to provide a radically new bioprinting technology to boost the performance of various engineered tissues which in turn will promote improved healthcare opportunities, as well as business and employment advances in the European Union and beyond.

Régimen de financiación

EIC - EIC

Coordinador

MYCRONIC AB
Aportación neta de la UEn
€ 381 875,00
Dirección
NYTORPSVAGEN 9
183 03 Taby
Suecia

Ver en el mapa

Región
Östra Sverige Stockholm Stockholms län
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 381 875,00

Participantes (4)